Oncology Burst
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
FDA approves pembrolizumab as adjuvant treatment for non-small cell lung cancer
ESMO is Europe’s leading medical oncology society, providing a professional network for its members and working with national societies across Europe.
We report long-term outcomes from a pooled analysis of patients with previously untreated metastatic non‒small-cell lung cancer (NSCLC) with programmed cell death ligand 1 (PD-L1)…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
AbstractKRASG12C inhibitors, like sotorasib and adagrasib, potently and selectively inhibit KRASG12C through a covalent interaction with the mutant cysteine, driving clinical efficacy in KRASG12C tumors.…
DATE: Friday 12th / Saturday 13th April 2024 VENUE: Johnstown House Hotel, Enfield, Co Meath
The detection of tumor DNA in the supernatant of guide sheath flush fluid collected during r-EBUS bronchoscopy represents a sensitive and complementary method for genotyping…
Uncommon EGFR mutations represent a rare subgroup of non-small cell lung cancer. Data on the efficacy of different generations of tyrosine kinase inhibitors (TKIs) in…
Mayo Clinic has been led by physicians since our founding more than 150 years ago, creating a culture of shared values that focus on putting…
Irish-US cancer collaboration celebrates twenty-fifth anniversary